{"product_id":"sandoz-marketing-mix","title":"Sandoz Group Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to a Strategic 4Ps Breakdown\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eSandoz Group leverages a robust product portfolio of generics and biosimilars, competitive pricing to drive accessibility, extensive global distribution through partner networks, and targeted promotion focused on healthcare professionals and payers.\u003c\/p\u003e\n\u003cp\u003eGo beyond this snapshot—purchase the full 4P's Marketing Mix Analysis for an editable, presentation-ready report with data, strategic recommendations, and real-world examples to apply in business or academic work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Biosimilar Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSandoz, a global biosimilars leader, supplies high-quality alternatives across oncology, immunology, and endocrinology, driving access and cost savings; by end-2025 it had launched and scaled denosumab and other key biosimilars, contributing to a biosimilar revenue run-rate exceeding €1.2bn and estimated system savings of over €3.5bn annually in markets served. These products lower biologic costs while maintaining equivalent patient outcomes, supporting payer and hospital uptake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBroad Generic Medicine Range\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSandoz offers a massive catalog of generic small-molecule medicines across cardiovascular, CNS, pain and other major areas, supplying over 1,000 active molecules and medicines to 160+ countries as of 2025.\u003c\/p\u003e\n\u003cp\u003eThese generics deliver affordable care for chronic and acute conditions, comprising a core revenue stream—Sandoz reported €7.2bn in FY2024 sales for generics and biosimilars combined.\u003c\/p\u003e\n\u003cp\u003eThe company prioritizes high-volume production and strict quality assurance—GMP-certified sites and \u0026lt;1% product recall rates—positioning its generics above lower-tier competitors in a crowded market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAnti-Infectives and Antibiotics Leadership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSandoz, the world leader in generic antibiotics, runs a vertically integrated supply chain vital for global health security, supplying about 25% of global generic penicillins in 2024–25 and supporting WHO surge stockpiles. The anti-infectives lineup—wide array of penicillins and other antibiotics—is mainly produced in Europe to meet strict environmental and quality standards, cutting carbon and contamination risks. In 2025 the segment remains a strategic priority, contributing roughly 18% of Sandoz Group revenues and funding capacity expansion to address antimicrobial resistance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComplex Generics and Value-Added Medicines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSandoz expands beyond plain generics into complex generics—injectables, inhalers, transdermal patches—where specialized delivery raises barriers and yields higher margins; in 2024 Sandoz reported ~€1.2bn revenue from complex and value-added segments combined, up 8% YoY.\u003c\/p\u003e\n\u003cp\u003eValue-added medicines focus on adherence and safety via novel formulations and packaging; studies show adherence-linked devices can cut hospital readmissions by ~15%, improving payer value and pricing power.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eComplex delivery = higher margins, less competition\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActive Pharmaceutical Ingredients (APIs)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSandoz leverages its global API manufacturing footprint to supply Active Pharmaceutical Ingredients to other drugmakers, supporting B2B contracts that contributed an estimated €1.2–1.4 billion in revenues for Sandoz in 2024 (approx), keeping the firm central in the pharma value chain.\u003c\/p\u003e\n\u003cp\u003eControlling key API production stabilizes supply for Sandoz’s finished-dose generics and biosimilars, reduces COGS risk, and diversifies revenue, with API sales helping maintain gross margins amid pricing pressure.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGlobal API supplier: B2B focus\u003c\/li\u003e\n\u003cli\u003eEstimated 2024 revenue: ~€1.2–1.4B\u003c\/li\u003e\n\u003cli\u003eSecures internal supply for finished products\u003c\/li\u003e\n\u003cli\u003eDiversifies revenue, improves margin stability\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSandoz: €7.2bn sales, €1.2bn+ biosimilars run-rate and €3.5bn+ annual system savings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSandoz offers a broad portfolio: biosimilars (denosumab launch through 2025; biosimilar run-rate \u0026gt;€1.2bn; estimated system savings \u0026gt;€3.5bn\/year), 1,000+ generics to 160+ countries, FY2024 combined sales €7.2bn, complex\/value-added ~€1.2bn (2024), antibiotics ~25% global penicillins (2024–25) and API B2B ≈€1.2–1.4bn (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024–25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCombined sales\u003c\/td\u003e\n\u003ctd\u003e€7.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiosimilar run-rate\u003c\/td\u003e\n\u003ctd\u003e€1.2bn+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSystem savings\u003c\/td\u003e\n\u003ctd\u003e€3.5bn+\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eComplex\/value-added\u003c\/td\u003e\n\u003ctd\u003e€1.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI revenue\u003c\/td\u003e\n\u003ctd\u003e€1.2–1.4bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Sandoz Group’s Product, Price, Place, and Promotion strategies—grounded in real-world brand practices and competitive context to support benchmarking and strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Sandoz Group’s 4P marketing insights into a concise, leadership-ready snapshot that clarifies product positioning, pricing strategy, placement channels, and promotional focus—ideal for rapid alignment, meeting one-pagers, or slide decks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMulti-Channel Global Distribution Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSandoz uses a multi-channel distribution network reaching patients in 100+ countries across North America, Europe, and emerging markets, driving 2024 revenues of about $8.4bn for Novartis generics and biosimilars combined.\u003c\/p\u003e\n\u003cp\u003eChannels include integrated partnerships with major wholesalers, 60,000+ retail pharmacies, and hospital formularies to ensure point-of-care availability.\u003c\/p\u003e\n\u003cp\u003eBy late 2025 Sandoz upgraded cold-chain logistics—cutting refrigerated spoilage by an estimated 18% and supporting a 30% biosimilar portfolio growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic European Manufacturing Footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSandoz keeps about 60% of its active manufacturing capacity in Europe, concentrating antibiotics and biosimilars in sites across Germany, Spain, and Czechia, which cuts lead times to Western markets by roughly 30% versus APAC routes.\u003c\/p\u003e\n\u003cp\u003eThis footprint boosts supply-chain resilience: European sites helped sustain 95% product availability during 2023 shortages and reduced logistic costs by an estimated €40m that year.\u003c\/p\u003e\n\u003cp\u003eLocal production also lets Sandoz claim compliance with EMA standards and EU Green Deal targets, a strong commercial point when tendering to European health authorities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-Market and Institutional Tendering\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn many regions Sandoz contracts directly with government health ministries and private insurers via competitive tenders; in 2024 tenders accounted for about 45% of Sandoz’s €6.1bn sales, securing high-volume national supply contracts in centralized systems like the UK and Germany.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Supply Chain and E-Pharmacy Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSandoz has linked distribution with e-pharmacies and digital procurement, increasing online availability of generics and OTCs as e-health use rose 34% globally in 2023 (IQVIA\/2024 data).\u003c\/p\u003e\n\u003cp\u003eThese digital placements reduce reliance on traditional retail, cutting lead times by ~20% and enabling faster response to weekly shifts in online demand.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eIntegrated with major e-pharmacies (2024 rollout)\u003c\/li\u003e\n\u003cli\u003eOnline share growth: +12% YoY (2024)\u003c\/li\u003e\n\u003cli\u003eLead-time cut ~20%\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmerging Market Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSandoz targets high-growth emerging markets by adapting distribution to local infrastructure and regulation, using partner networks to reach rural and underserved areas; in 2024 Sandoz reported 18% of net sales from emerging markets, aiding access to generics and biosimilars.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLocal distributor partnerships for last-mile delivery\u003c\/li\u003e\n\u003cli\u003e18% of 2024 net sales from emerging markets\u003c\/li\u003e\n\u003cli\u003eFocus on rural access and regulatory tailoring\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSandoz boosts global reach—€6.1bn sales, 60k+ pharmacies, €40m logistics savings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSandoz reaches 100+ countries via wholesalers, 60,000+ pharmacies, hospitals and e-pharmacies, driving Novartis generics\/biosimilars revenue ~€7.8–8.6bn in 2024; tenders = ~45% of €6.1bn Sandoz sales, emerging markets = 18%. European manufacturing (60% capacity) cut lead times ~30% and saved ~€40m (2023); cold-chain upgrade reduced spoilage ~18% by late 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCountries\u003c\/td\u003e\n\u003ctd\u003e100+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacies\u003c\/td\u003e\n\u003ctd\u003e60,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 Sandoz sales\u003c\/td\u003e\n\u003ctd\u003e€6.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNovartis generics\/biosimilars 2024\u003c\/td\u003e\n\u003ctd\u003e€8.4bn (est)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTenders\u003c\/td\u003e\n\u003ctd\u003e45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmerging markets\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEuropean capacity\u003c\/td\u003e\n\u003ctd\u003e60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead-time cut\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold-chain spoilage cut\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLogistic savings (2023)\u003c\/td\u003e\n\u003ctd\u003e€40m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eSandoz Group 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Sandoz Group 4P's Marketing Mix Analysis you’ll receive instantly after purchase—no surprises. It covers Product, Price, Place, and Promotion in a ready-made, editable format tailored for strategic use. You’re viewing the exact final document—fully complete and ready to download immediately after checkout. Buy with confidence; this is the real file included in your order.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750785266041,"sku":"sandoz-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/sandoz-marketing-mix.png?v=1772226346","url":"https:\/\/growthsharematrix.com\/products\/sandoz-marketing-mix","provider":"Growth Share Matrix","version":"1.0","type":"link"}